Following fields are empty!
Neurology and Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Oncology and Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Ophthalmology and Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Pain and Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Pediatric Drugs
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Institutional Agreement
FinELib-konsortion solmima sopimus Springer Naturen kanssa vuosille 2024-2025 sisältää vastaaville kirjoittajille oikeuden julkaista artikkeleita avoimena ilman lisämaksua Springer Compact -kokoelman hybridilehdissä sopimuskauden aikana. Julkaista voi myös edellisen ja nykyisen sopimuskauden aikana hybridistä täysin avoimeksi muuttuvassa nimekkeessä, joka sisältyy lehtilistaan.FinELib consortium’s agreement with Springer Nature for the years 2024-2025 includes open access publishing for corresponding authors in Springer's hybrid titles in Compact collection without extra charge during the agreement term. Additionally publishing is possible in titles included in the list that transitioned from hybrid to fully OA during the previous agreement term or do so during the current agreement term.
- Ohjeita julkaisemiseen FinELibin sivuilla: Artikkelin julkaiseminen avoimena Springer Compact lehdissä
- Instructions on publishing on FinELib's pages: Open Access Publishing in Springer Compact Journals
Pharmaceutical Medicine
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Institutional Agreement
FinELib-konsortion solmima sopimus Springer Naturen kanssa vuosille 2024-2025 sisältää vastaaville kirjoittajille oikeuden julkaista artikkeleita avoimena ilman lisämaksua Springer Compact -kokoelman hybridilehdissä sopimuskauden aikana. Julkaista voi myös edellisen ja nykyisen sopimuskauden aikana hybridistä täysin avoimeksi muuttuvassa nimekkeessä, joka sisältyy lehtilistaan.FinELib consortium’s agreement with Springer Nature for the years 2024-2025 includes open access publishing for corresponding authors in Springer's hybrid titles in Compact collection without extra charge during the agreement term. Additionally publishing is possible in titles included in the list that transitioned from hybrid to fully OA during the previous agreement term or do so during the current agreement term.
- Ohjeita julkaisemiseen FinELibin sivuilla: Artikkelin julkaiseminen avoimena Springer Compact lehdissä
- Instructions on publishing on FinELib's pages: Open Access Publishing in Springer Compact Journals
PharmacoEconomics
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Institutional Agreement
FinELib-konsortion solmima sopimus Springer Naturen kanssa vuosille 2024-2025 sisältää vastaaville kirjoittajille oikeuden julkaista artikkeleita avoimena ilman lisämaksua Springer Compact -kokoelman hybridilehdissä sopimuskauden aikana. Julkaista voi myös edellisen ja nykyisen sopimuskauden aikana hybridistä täysin avoimeksi muuttuvassa nimekkeessä, joka sisältyy lehtilistaan.FinELib consortium’s agreement with Springer Nature for the years 2024-2025 includes open access publishing for corresponding authors in Springer's hybrid titles in Compact collection without extra charge during the agreement term. Additionally publishing is possible in titles included in the list that transitioned from hybrid to fully OA during the previous agreement term or do so during the current agreement term.
- Ohjeita julkaisemiseen FinELibin sivuilla: Artikkelin julkaiseminen avoimena Springer Compact lehdissä
- Instructions on publishing on FinELib's pages: Open Access Publishing in Springer Compact Journals
PharmacoEconomics - Open
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Pulmonary Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Rheumatology and Therapy
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Targeted Oncology
Despite the major efforts made in oncology over the past ten years, only relatively modest improvements have been made in the conventional treatment of cancer. Recently, a better understanding of molecular pathways has provided pathologists with clues to the parthenogenesis of the disease and multiple targets for new strategies. New treatments, monoclonal antibodies or small molecules, have emerged targeting these pathways and inhibiting tumor growth and progression. These 'mabs' and 'nibs' constitute a new language with its own grammar that oncologists have to learn. Significant work remains in controlling theses processes and understanding these new compounds. This journal aims to be a pragmatic tool for all physicians committed to the field, focusing on insight into the basic science of cellular functions, critical reviews of clinical data. The Société française d'angiogenèse is affiliated to the journal.
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Institutional Agreement
FinELib-konsortion solmima sopimus Springer Naturen kanssa vuosille 2024-2025 sisältää vastaaville kirjoittajille oikeuden julkaista artikkeleita avoimena ilman lisämaksua Springer Compact -kokoelman hybridilehdissä sopimuskauden aikana. Julkaista voi myös edellisen ja nykyisen sopimuskauden aikana hybridistä täysin avoimeksi muuttuvassa nimekkeessä, joka sisältyy lehtilistaan.FinELib consortium’s agreement with Springer Nature for the years 2024-2025 includes open access publishing for corresponding authors in Springer's hybrid titles in Compact collection without extra charge during the agreement term. Additionally publishing is possible in titles included in the list that transitioned from hybrid to fully OA during the previous agreement term or do so during the current agreement term.
- Ohjeita julkaisemiseen FinELibin sivuilla: Artikkelin julkaiseminen avoimena Springer Compact lehdissä
- Instructions on publishing on FinELib's pages: Open Access Publishing in Springer Compact Journals
The Patient - Patient-Centered Outcomes Research
Compliant Options - Provided by Journal Checker Tool
Go ahead and submit. Remember to select a CC BY licence to ensure compliance.
Select the open access publishing option with a https://creativecommons.org/licenses/by/2.0/ license to ensure compliance.
Select the open access publishing option with a CC BY license to ensure compliance.
Go ahead and submit. Remember to select a CC BY license to ensure compliance.
Following acceptance, please deposit your author accepted manuscript in a repository without embargo.
Your funder’s grant conditions set out how you can retain sufficient rights to self-archive the Author Accepted Manuscript in any OA repository. Publishing fees do not apply with this route.
Unfortunately, this journal has no Plan-S compliant options - Provided by Journal Checker Tool
Institutional Agreement
FinELib-konsortion solmima sopimus Springer Naturen kanssa vuosille 2024-2025 sisältää vastaaville kirjoittajille oikeuden julkaista artikkeleita avoimena ilman lisämaksua Springer Compact -kokoelman hybridilehdissä sopimuskauden aikana. Julkaista voi myös edellisen ja nykyisen sopimuskauden aikana hybridistä täysin avoimeksi muuttuvassa nimekkeessä, joka sisältyy lehtilistaan.FinELib consortium’s agreement with Springer Nature for the years 2024-2025 includes open access publishing for corresponding authors in Springer's hybrid titles in Compact collection without extra charge during the agreement term. Additionally publishing is possible in titles included in the list that transitioned from hybrid to fully OA during the previous agreement term or do so during the current agreement term.
- Ohjeita julkaisemiseen FinELibin sivuilla: Artikkelin julkaiseminen avoimena Springer Compact lehdissä
- Instructions on publishing on FinELib's pages: Open Access Publishing in Springer Compact Journals